Vivace Therapeutics’ VT3989 for mesothelioma gains FDA Orphan Drug Designation

VT3989 has been evaluated in an ongoing Phase I clinical study involving over 200 patients with refractory metastatic solid tumours. Credit: National Cancer Institute/Unsplash.com.